Hillsborough, NJ – According to filings with the U.S. Securities and Exchange Commission, Ceptur Therapeutics is raising $74,999,978.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Keith Dewedoff played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ceptur Therapeutics
Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases. The Company’s proprietary U1 Adaptor technology controls gene-specific expression and affords advantageous properties for drugging difficult targets. U1 Adaptors are bivalent oligonucleotides that engage sequence-specific mRNA and the U1 small nuclear ribonuclear protein (U1 snRNP), which is a ubiquitous intracellular machine that regulates transcription and splicing. U1 Adaptor therapeutics control gene expression at the pre-mRNA level within the nucleus.

To learn more about Ceptur Therapeutics, visit http://cepturtx.com/

Contact:
Keith Dewedoff, Chief Financial Officer
215-330-8399
kdewedoff@cepturtx.com
https://www.linkedin.com/in/dewedoffk/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved